文献速递白血病

种族与民族和儿童急性髓系白血病临床表型、遗传学及生存的关联

Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该研究利用TARGET数据库分析儿童AML中种族-民族与细胞遗传学、临床特征及生存的关联。相比白人非西班牙裔,t(8;21) AML在黑人(OR 2.22)和西班牙裔(OR 1.74)中更常见,不良预后的KMT2A重排t(6;11)在黑人中更常见(OR 6.12)。在KMT2Ar和CBF AML中,黑人和西班牙裔患者生存更差,但接受吉妥珠单抗奥唑米星(GO)治疗者未发现该差异。

要点

  • 黑人儿童t(8;21) AML风险更高(OR 2.22),西班牙裔亦高(OR 1.74)。
  • 黑人儿童KMT2A重排t(6;11)风险显著更高(OR 6.12)。
  • KMT2Ar和CBF AML中黑人和西班牙裔生存更差,GO治疗者未见差异。

核心结论

  • 儿童AML生存的种族-民族差异显著且因细胞遗传学亚型而异。

研究设计与样本

  • 基于TARGET数据库的回顾性队列研究,分析儿童AML中种族-民族与细胞遗传学、临床特征及生存的关联。

主要发现

  • 相比白人非西班牙裔,t(8;21) AML在黑人中更常见(OR 2.22,95%CI 1.28-3.74),在西班牙裔中更常见(OR 1.74,95%CI 1.05-2.83)。
  • KMT2A重排t(6;11)(q27;q23)在黑人中更常见(OR 6.12,95%CI 1.81-21.59)。
  • KMT2Ar AML中,黑人无事件生存(EFS)更差(HR 2.31,95%CI 1.41-3.79),总生存(OS)更差(HR 2.54,95%CI 1.43-4.51);西班牙裔EFS更差(HR 2.20,95%CI 1.27-3.80),OS更差(HR 2.07,95%CI 1.09-3.93)。
  • CBF AML中,黑人EFS更差(HR 1.93,95%CI 1.14-3.28),OS更差(HR 3.24,95%CI 1.60-6.57)。
  • 接受吉妥珠单抗奥唑米星(GO)治疗的患者中未检测到该差异。

临床怎么用

  • 临床应关注黑人及西班牙裔儿童AML患者中特定高危遗传亚型的生存差异。
  • GO治疗可能缩小部分遗传亚型中的生存差异,需进一步验证。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Black and Hispanic children with acute myeloid leukemia (AML) have worse outcomes compared with White children. AML is a heterogeneous disease with numerous genetic subtypes in which these disparities have not been specifically investigated. In this study, we used the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database to examine the association of race-ethnicity with leukemia cytogenetics, clinical features, and survival outcomes within major cytogenetic subgroups of pediatric AML. Compared with White non-Hispanic patients, t(8;21) AML was more prevalent among Black (odds ratio [OR], 2.22; 95% confidence interval [CI], 1.28-3.74) and Hispanic patients (OR, 1.74; 95% CI, 1.05-2.83). The poor prognosis KMT2A rearrangement t(6;11)(q27;q23) was more prevalent among Black patients (OR, 6.12; 95% CI, 1.81-21.59). Among those with KMT2Ar AML, Black race was associated with inferior event-free survival (EFS) (hazard ratio [HR], 2.31; 95% CI, 1.41-3.79) and overall survival (OS) (HR, 2.54; 1.43-4.51). Hispanic patients with KMT2Ar AML also had inferior EFS (HR, 2.20; 95% CI, 1.27-3.80) and OS (HR, 2.07; 95% CI, 1.09-3.93). Similarly, among patients with t(8;21) or inv(16) AML (ie, core-binding factor [CBF] AML), Black patients had inferior outcomes (EFS HR, 1.93; 95% CI, 1.14-3.28 and OS HR, 3.24; 95% CI, 1.60-6.57). This disparity was not detected among patients receiving gemtuzumab ozogamicin (GO). In conclusion, racial-ethnic disparities in survival outcomes among young people with AML are prominent and vary across cytogenetic subclasses. Future studies should explore the socioeconomic and biologic determinants of these disparities.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Conneely SE, McAtee CL, Gupta R, et al. Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia. Blood Adv. 2021. PMID: 34619758. doi:10.1182/bloodadvances.2021004735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。